EA200700656A1 - Стабильные жидкие композиции плазмидной днк - Google Patents

Стабильные жидкие композиции плазмидной днк

Info

Publication number
EA200700656A1
EA200700656A1 EA200700656A EA200700656A EA200700656A1 EA 200700656 A1 EA200700656 A1 EA 200700656A1 EA 200700656 A EA200700656 A EA 200700656A EA 200700656 A EA200700656 A EA 200700656A EA 200700656 A1 EA200700656 A1 EA 200700656A1
Authority
EA
Eurasian Patent Office
Prior art keywords
plasmid dna
plasmid
dna
stable liquid
relates
Prior art date
Application number
EA200700656A
Other languages
English (en)
Other versions
EA011554B1 (ru
Inventor
Франсис БЛАНШ
Мишель Кудер
Николя Мастрали
Тьерри Гиллемэн
Давид Гайак
Original Assignee
Сентелион
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2004/011437 external-priority patent/WO2005026331A2/en
Priority claimed from PCT/EP2005/005213 external-priority patent/WO2005100542A1/en
Application filed by Сентелион filed Critical Сентелион
Publication of EA200700656A1 publication Critical patent/EA200700656A1/ru
Publication of EA011554B1 publication Critical patent/EA011554B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C12N15/68—Stabilisation of the vector
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor

Abstract

Данное изобретение относится к стабильным жидким препаратам плазмидной ДНК, которая остается не деградированной от +4°С до комнатной температуры в течение длительных периодов времени, и, таким образом, они приемлемы для хранения плазмидной ДНК, применяемой для исследований, основанной на плазмидах терапии, как, например, ДНК-вакцина и средства генной терапии. Настоящее изобретение также относится к способу хранения плазмидной ДНК в стабильной форме во времени от +4°С до комнатной температуры. Настоящее изобретение также относится к жидким композициям стабильной плазмидной ДНК для применения в способе лечения человеческого организма или организма животного посредством основанной на плазмидах терапии, как, например, ДНК-вакцинация или генная терапия.
EA200700656A 2004-09-17 2005-09-19 Стабильные жидкие композиции плазмидной днк EA011554B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/EP2004/011437 WO2005026331A2 (en) 2003-09-17 2004-09-17 Method of preparation of pharmaceutically grade plasmid dna
PCT/EP2005/005213 WO2005100542A1 (en) 2004-04-19 2005-04-19 Method for purifying plasmid dna
PCT/EP2005/010881 WO2006029908A1 (en) 2004-09-17 2005-09-19 Stable liquid formulations of plasmid dna

Publications (2)

Publication Number Publication Date
EA200700656A1 true EA200700656A1 (ru) 2007-10-26
EA011554B1 EA011554B1 (ru) 2009-04-28

Family

ID=56290732

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200700656A EA011554B1 (ru) 2004-09-17 2005-09-19 Стабильные жидкие композиции плазмидной днк

Country Status (14)

Country Link
EP (1) EP1791945A1 (ru)
JP (1) JP2008512997A (ru)
KR (1) KR20070058621A (ru)
CN (1) CN101040041A (ru)
AU (1) AU2005284244A1 (ru)
BR (1) BRPI0515553A (ru)
CA (1) CA2579340A1 (ru)
EA (1) EA011554B1 (ru)
IL (1) IL181753A0 (ru)
MX (1) MX2007003214A (ru)
NO (1) NO20071946L (ru)
NZ (1) NZ553914A (ru)
TN (1) TNSN07087A1 (ru)
WO (1) WO2006029908A1 (ru)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2542385C2 (ru) 2012-08-31 2015-02-20 Общество с ограниченной ответственностью "НекстГен" Способ получения фармацевтической композиции для индукции развития кровеносных сосудов в тканях, фармацевтическая композиция, полученная этим способом, и способ лечения ишемии тканей и/или органов человека
CN104032005B (zh) * 2014-06-12 2015-11-25 成都中创清科医学检验所有限公司 一种pcr测序中间产物的保存剂及保存方法
EP3241903A4 (en) * 2014-12-29 2018-07-04 Bonac Corporation Composition containing nucleic acid molecule stably
RU2612497C2 (ru) 2015-05-26 2017-03-09 Общество с ограниченной ответственностью "НекстГен" Оптимизированная нуклеотидная последовательность и фармацевтическая композиция на ее основе с пролонгированной экспрессией трансгена vegf
RU2628087C1 (ru) * 2016-09-01 2017-08-14 Игорь Валериевич Корниенко Композиция с противомикробным действием для хранения днк или днк-содержащих препаратов (варианты) и её применение
CN106554956A (zh) * 2016-12-07 2017-04-05 安徽智飞龙科马生物制药有限公司 一种产业化制备BCG‑CpG‑DNA的方法
CN110869501B (zh) * 2017-08-01 2023-08-18 深圳华大智造科技股份有限公司 一种高效的内切酶缓冲液体系
CA3073462A1 (en) 2017-08-25 2019-02-28 Zoetis Services Llc A method of immobilizing a nucleic acid probe to a solid support
CN111433584B (zh) * 2017-11-22 2023-10-31 拜克门寇尔特公司 稀释剂制备模块和单元
CN112639119A (zh) * 2018-08-30 2021-04-09 葛兰素史密斯克莱知识产权发展有限公司 检测核酸的方法
CN111718961B (zh) * 2019-07-03 2022-02-08 华大青兰生物科技(无锡)有限公司 一种用质粒转化细菌的方法
CN115404232A (zh) * 2021-05-10 2022-11-29 艾棣维欣(苏州)生物制品有限公司 用于提取细菌中质粒dna的方法
KR20230141965A (ko) * 2022-03-24 2023-10-10 주식회사 헬릭스미스 플라스미드 dna를 포함하는 액체제형 약제학적 조성물

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7807822B2 (en) * 1996-08-01 2010-10-05 Robert Bridenbaugh Methods for purifying nucleic acids
FR2773818B1 (fr) * 1998-01-21 2000-02-18 Pasteur Merieux Serums Vacc Procede et dispositif de lyse de bacteries
AU782193B2 (en) * 1999-12-17 2005-07-07 Merck & Co., Inc. Polynucleotide vaccines expressing codon optimized HIV-1 Nef and modified HIV-1 Nef

Also Published As

Publication number Publication date
NO20071946L (no) 2007-05-29
CN101040041A (zh) 2007-09-19
TNSN07087A1 (en) 2008-06-02
WO2006029908A1 (en) 2006-03-23
CA2579340A1 (en) 2006-03-23
BRPI0515553A (pt) 2008-07-29
KR20070058621A (ko) 2007-06-08
NZ553914A (en) 2009-11-27
AU2005284244A1 (en) 2006-03-23
EP1791945A1 (en) 2007-06-06
JP2008512997A (ja) 2008-05-01
MX2007003214A (es) 2007-10-11
IL181753A0 (en) 2007-07-04
EA011554B1 (ru) 2009-04-28

Similar Documents

Publication Publication Date Title
EA200700656A1 (ru) Стабильные жидкие композиции плазмидной днк
BR0210839A (pt) Sistema de recombinação, método para remover uma sequência de dna do dna cromossÈmico de uma célula ou organismo eucarióticos, organismo, cultura de célula, órgão, tecido, parte ou material de propagação transgênico, e, uso de um organismo ou de uma cultura de célula, órgão, tecido, parte ou material de propagação transgênico
SG146691A1 (en) Methods of preparing and using stem cell compositions and kits comprising the same
MX2007007602A (es) Agonistas del peptido 1 similar al glucagon, composiciones, metodos y usos.
BRPI0414867A (pt) pirazolopiridinas e seus análogos
WO2005062881A3 (en) Gene therapy using transposon-based vectors
SG151315A1 (en) Human glp-1 mimetibodies, compositions, methods and uses
NO20044940L (no) Rekombinant poxvirus som uttrykker homologe gener innsatt i det poxvirale genomet
SG10201903381TA (en) Artificial nucleic acid molecules
MX9708854A (es) Terapia de genes para regulacion de celulas efectoras.
BR112015005674A2 (pt) variantes e métodos de uso de hppd
AR061930A1 (es) Mimeticuerpos de glp-1 humanos, composiciones, metodos y usos
MX2007004841A (es) Triazoles utiles como inhibidores de proteinas cinasas.
MX2020010871A (es) Compuestos de 5'-caperuza-trinucleótidos u oligonucleótidos superiores y sus usos en estabilizar arn, que expresan proteínas y en la terapia.
CY1112867T1 (el) Πεπτιδια επιτοπων που προερχονται απο τον υποδοχεα 1 του αγγειακου ενδοθηλιακου αυξητικου παραγοντα και εμβολια περιεχοντας αυτα τα πεπτιδια
DE602004028029D1 (en) Rwendung
ATE527377T1 (de) Erstellung von genexpressionprofilen aus ffpe- proben
WO2005047469A3 (en) PORCINE ISOGLOBOSIDE 3 SYNTHASE PROTEIN, cDNA, GENOMIC ORGANIZATION, AND REGULATORY REGION
DE69833876D1 (de) Zusammensetzungen und methoden zur zielgerichteten abgabe von biologisch aktivenfaktoren
WO2019098759A3 (ko) 형질전환된 인간세포 및 이의 용도
UY29544A1 (es) Tratamiento de enfermedades usando un sistema mejorado de expresión regulada
NO20051561L (no) Nukleinsyremolekyler som koder for humant papillomavirus og anvendelse av disse i vaksine.
EA200700346A1 (ru) Бактериофаг- и профаг-специфические протеины в генной терапии рака
ATE552272T1 (de) Myostatin-isoform
TW200833836A (en) An improved method of cultivating the Cordyceps Militaris by adding sugar cane fiber

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU